Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in milestones

Jazz Pharmaceuticals plc

Upfront consideration of $820M; contingent milestones up to $500M (ABS-1230 regulatory approval and sales thresholds).
Milestones: $250M on regulatory approval for ABS-1230 in KCNT1-Related Epilepsy; $100M at $500M annual sales; $150M at $1B annual sales.
Spin-Out: non-ABS-1230 programs transferred to SpinCo; Jazz retains minority equity stake.
Closing conditions: HSR clearance, 85% stockholder approval, Spin-Out completion, no termination fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.